Long-acting beta2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: a systematic review
Shukla VK, Husereau DR, Boucher M, Mensinkai S, Dales R
Record ID 32002000901
English, French
Authors' objectives:
This report aims to determine, through a systematic review of the literature, the efficacy and safety of salmeterol and formoterol for patients with stable non-reversible chronic obstructive pulmonary disease (COPD) as compared to: - placebo with or without the additional use of short-acting beta2-agonists; and - anticholinergics with or without the additional use of short-acting beta2-agonists
For the purpose of this assessment, COPD was considered stable if there had been no infections, flare-ups or hospitalizations in the past month.
Authors' recommendations:
The review found that, compared to placebo, the long-acting beta2-agonists are superior in decreasing the use of rescue inhalers. However, they did not improve functional outcomes, such as distance travelled in a six-minute walk test. Two reports identified in the literature search compared the efficacy of long-acting beta2-agonists with ipratropium bromide. Neither report showed salmeterol or formoterol to be more efficacious in the patient group studied.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Bronchodilator Agents
- Pulmonary Disease, Chronic Obstructive
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.